Yarvitan

RSS
Withdrawn

This medicine's authorisation has been withdrawn

mitratapide
MedicineVeterinaryWithdrawn
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for this product has been withdrawn at the request of the marketing authorisation holder.

español (ES) (256.72 KB - PDF)

View

čeština (CS) (393.52 KB - PDF)

View

dansk (DA) (256.17 KB - PDF)

View

Deutsch (DE) (257.38 KB - PDF)

View

eesti keel (ET) (255.5 KB - PDF)

View

ελληνικά (EL) (454.41 KB - PDF)

View

français (FR) (257.52 KB - PDF)

View

italiano (IT) (256.43 KB - PDF)

View

latviešu valoda (LV) (399.71 KB - PDF)

View

lietuvių kalba (LT) (373.07 KB - PDF)

View

magyar (HU) (384.35 KB - PDF)

View

Nederlands (NL) (256.77 KB - PDF)

View

polski (PL) (403.94 KB - PDF)

View

português (PT) (257.16 KB - PDF)

View

slovenčina (SK) (389.05 KB - PDF)

View

slovenščina (SL) (380.7 KB - PDF)

View

Suomi (FI) (255.8 KB - PDF)

View

svenska (SV) (256.06 KB - PDF)

View

Product information

български (BG) (876.69 KB - PDF)

View

español (ES) (368.06 KB - PDF)

View

čeština (CS) (682.61 KB - PDF)

View

dansk (DA) (413.04 KB - PDF)

View

Deutsch (DE) (363.22 KB - PDF)

View

eesti keel (ET) (360.22 KB - PDF)

View

ελληνικά (EL) (926.55 KB - PDF)

View

français (FR) (369.55 KB - PDF)

View

italiano (IT) (358.34 KB - PDF)

View

latviešu valoda (LV) (723.79 KB - PDF)

View

lietuvių kalba (LT) (500.34 KB - PDF)

View

magyar (HU) (667.24 KB - PDF)

View

Malti (MT) (707.97 KB - PDF)

View

Nederlands (NL) (359.17 KB - PDF)

View

polski (PL) (707.86 KB - PDF)

View

português (PT) (369.01 KB - PDF)

View

română (RO) (511.36 KB - PDF)

View

slovenčina (SK) (679.07 KB - PDF)

View

slovenščina (SL) (667.27 KB - PDF)

View

Suomi (FI) (355.26 KB - PDF)

View

svenska (SV) (366.58 KB - PDF)

View
Latest procedure affecting product information:II/0003
20/10/2008

български (BG) (312.24 KB - PDF)

View

español (ES) (232.03 KB - PDF)

View

čeština (CS) (307.25 KB - PDF)

View

dansk (DA) (233.01 KB - PDF)

View

Deutsch (DE) (235.26 KB - PDF)

View

eesti keel (ET) (231.11 KB - PDF)

View

ελληνικά (EL) (308.87 KB - PDF)

View

français (FR) (231.59 KB - PDF)

View

italiano (IT) (231.31 KB - PDF)

View

latviešu valoda (LV) (309.08 KB - PDF)

View

lietuvių kalba (LT) (262.26 KB - PDF)

View

magyar (HU) (304.77 KB - PDF)

View

Malti (MT) (309.64 KB - PDF)

View

Nederlands (NL) (234.5 KB - PDF)

View

polski (PL) (274.42 KB - PDF)

View

português (PT) (231.94 KB - PDF)

View

română (RO) (295.75 KB - PDF)

View

slovenčina (SK) (306.51 KB - PDF)

View

slovenščina (SL) (304.86 KB - PDF)

View

Suomi (FI) (231.26 KB - PDF)

View

svenska (SV) (231.79 KB - PDF)

View

Product details

Name of medicine
Yarvitan
Active substance
mitratapide
International non-proprietary name (INN) or common name
mitratapide
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QA08AB90

Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

Therapeutic indication

As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management programme which also includes appropriate dietary changes. Introducing appropriate lifestyle changes (e.g. increased exercise), in conjunction with this weight management programme, may provide additional benefits.

Authorisation details

EMA product number
EMEA/V/C/000113
Marketing authorisation holder
Janssen Pharmaceutica N.V.

Turnhoutseweg 30
B-2340 Beerse
Belgium

Marketing authorisation issued
14/11/2006
Revision
3

Assessment history

This page was last updated on

Share this page